NeoGenomics (NEO) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Abhishek Jain President and Chief Operating Officer — Warren Stone Vice President, Investor Relations — Priya Vedaraman TAKEAWAYS Total Revenue -- $186.7 million, representing 11% growth year over year and surpassing previously issued guidance. Clinical Revenue -- $171.2 million, reflecting 14% year-over-year growth driven by demand, 6% higher volumes, and 8% increase in average unit price (AUP). NGS (Next-Generation Sequencing) Revenue -- Grew 26% year over year and now constitutes approximately one third of clinical revenue, with growth ahead of NGS market rates. Adjusted EBITDA -- $9 million for the quarter, up 27% year over year, with margin expanding by approximately 60 basis points. Adjusted Gross Margin -- 46%, decreasing by 80 basis points due to Pathline acquisition dilution and PanTracer Liquid launch prior to MolDX approval, offset partly by higher AUP and lab efficiency gains. Non-Clinical Revenue -- $15.5 million, representing
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- Wall Street's Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets [TheStreet.com]TheStreet.com
- NeoGenomics (NEO) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $25.00 price target on the stock.MarketBeat
- NeoGenomics (NEO) was upgraded by Benchmark Co. from "hold" to "buy".MarketBeat
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- NeoGenomics's (NASDAQ:NEO) Q1 CY2026: Beats On Revenue [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 4/28/26 - Beat
NEO
Sec Filings
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- 4/6/26 - Form DEFA14A
- NEO's page on the SEC website